High rate of per oral mecillinam treatment failure in community-Acquired urinary tract infections caused by ESBL-producing escherichia coli

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Søraas, Arne ^a   Sundsfjord, Arnfinn ^b,c   Jørgensen, Silje Bakken ^a   Liestøl, Knut ^d   Jenum, Pal A ^a,e  

^a Vestre Viken Hospital Trust   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFOTAXIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; MECILLINAM; NITROFURANTOIN; TRIMETHOPRIM;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM ISOLATE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ESCHERICHIA COLI; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NONHUMAN; NORWAY; POPULATION RESEARCH; PROSPECTIVE STUDY; QUESTIONNAIRE; URINALYSIS; URINARY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMDINOCILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; TREATMENT FAILURE; URINARY TRACT INFECTIONS; YOUNG ADULT;

EID: 84898629855     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0085889     Document Type: Article

References (36)

1. Garau J(2008) Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline. Clin Microbiol Infect 14 Suppl 1: 198-202 (Pubitemid 350269204)
2. Sougakoff W, Jarlier V(2000) Comparative potency of mecillinam and other beta-lactam antibiotics against Escherichia coli strains producing different betalactamases. J Antimicrob Chemother 46 Suppl 1: 9-14
3. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R et al.(2011) International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 52: e103-e120
4. Dewar S, Reed LC, Koerner RJ(2013) Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother
5. Sullivan A, Edlund C, Svenungsson B, Emtestam L, Nord CE(2001) Effect of perorally administered pivmecillinam on the normal oropharyngeal, intestinal and skin microflora. J Chemother 13: 299-308 (Pubitemid 32577096)
6. Sullivan A, Fianu-Jonasson A, Landgren BM, Nord CE(2005) Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. Antimicrob Agents Chemother 49: 170-175 (Pubitemid 40065789)
7. Kahlmeter G, Poulsen HO(2012) Antimicrobial susceptibility of Escherichia coli from community-Acquired urinary tract infections in Europe: the ECO.SENS study revisited. Int J Antimicrob Agents 39: 45-51
8. NORM/NORM-VET 2010(2011) Usage of Antimicrobial Agents and Occurrence of Antimicrobial Resistance in Norway. Tromsø/Oslo 2011. ISSN:1502-2307(print)/1890-9965(electronic)
9. Tarnberg M, Ostholm-Balkhed A, Monstein HJ, Hallgren A, Hanberger H et al.(2011) In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 30: 981-987
10. Titelman E, Iversen A, Kalin M, Giske CG(2012) Efficacy of pivmecillinam for treatment of lower urinary tract infection caused by extended-spectrum betalactamase- producing Escherichia coli and Klebsiella pneumoniae. Microb Drug Resist 18: 189-192
11. Auer S, Wojna A, Hell M(2010) Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta- lactamaseproducing Escherichia coli. Antimicrob Agents Chemother 54: 4006-4008
12. Wootton M, Walsh TR, Macfarlane L, Howe RA(2010) Activity of mecillinam against Escherichia coli resistant to third-generation cephalosporins. J Antimicrob Chemother 65: 79-81
13. Lampri N, Galani I, Poulakou G, Katsarolis I, Petrikkos G et al.(2012) Mecillinam/clavulanate combination: a possible option for the treatment of community-Acquired uncomplicated urinary tract infections caused by extendedspectrum beta-lactamase-producing Escherichia coli. J Antimicrob Chemother 67: 2424-2428
14. Thomas K, Weinbren MJ, Warner M, Woodford N, Livermore D(2006) Activity of mecillinam against ESBL producers in vitro. J Antimicrob Chemother 57: 367-368 (Pubitemid 43160188)
15. Nicolle LE, Mulvey MR(2007) Successful treatment of ctx-m ESBL producing Escherichia coli relapsing pyelonephritis with long term pivmecillinam. Scand J Infect Dis 39: 748-749 (Pubitemid 47180483)
16. Soraas A, Sundsfjord A, Sandven I, Brunborg C, Jenum PA(2013) Risk Factors for Community-Acquired Urinary Tract Infections Caused by ESBL-Producing Enterobacteriaceae -A Case-Control Study in a Low Prevalence Country. PLoS One 8: e69581
17. Berg C, Furu K, Mahic M, Litleskare I, Rønning M et al.(2011) The Norwegian Prescription Database 2006-2010: The Norwegian Institute of Public Health. ISBN: 978-82-8082-458-5
18. European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Available: http://www.eucast. org/Accessed 1 October 2013
19. Birkett CI, Ludlam HA, Woodford N, Brown DF, Brown NM et al.(2007) Realtime TaqMan PCR for rapid detection and typing of genes encoding CTX-M extended-spectrum beta-lactamases. J Med Microbiol 56: 52-55 (Pubitemid 46036275)
20. Tofteland S, Haldorsen B, Dahl KH, Simonsen GS, Steinbakk M et al.(2007) Effects of phenotype and genotype on methods for detection of extendedspectrum- beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway. J Clin Microbiol 45: 199-205 (Pubitemid 46106427)
21. Lawrenson RA, Logie JW(2001) Antibiotic failure in the treatment of urinary tract infections in young women. J Antimicrob Chemother 48: 895-901 (Pubitemid 33735327)
22. Goettsch WG, Janknegt R, Herings RM(2004) Increased treatment failure after 3-days' courses of nitrofurantoin and trimethoprim for urinary tract infections in women: a population-based retrospective cohort study using the PHARMO database. Br J Clin Pharmacol 58: 184-189 (Pubitemid 39043999)
23. Bjerrum L, Dessau RB, Hallas J(2002) Treatment failures after antibiotic therapy of uncomplicated urinary tract infections. A prescription database study. Scand J Prim Health Care 20: 97-101 (Pubitemid 34764226)
24. Viera AJ, Garrett JM(2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37: 360-363 (Pubitemid 40656185)
25. Livermore DM(2012) Current epidemiology and growing resistance of gramnegative pathogens. Korean J Intern Med 27: 128-142
26. Naseer U, Sundsfjord A(2011) The CTX-M conundrum: dissemination of plasmids and Escherichia coli clones. Microb Drug Resist 17: 83-97
27. Craig WA(2003) Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 17: 479-501 (Pubitemid 38029149)
28. Kerrn MB, Frimodt-Moller N, Espersen F(2004) Urinary concentrations and urine ex-vivo effect of mecillinam and sulphamethizole. Clin Microbiol Infect 10: 54-61 (Pubitemid 38128593)
29. Jensen KS, Henriksen AS, Frimodt-Moeller N(2008) Pivmecillinam: estimation of adequate dosage for susceptible and ESBL-producing E. coli by Monte Carlo PK/PD simulation. Abstracts of the 18nd European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2008 Abstract P1255 European Society of Clinical Microbiology and Infectious Diseases, Basel, Switzerland
30. Hvidberg H, Struve C, Krogfelt KA, Christensen N, Rasmussen SN et al.(2000) Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies. Antimicrob Agents Chemother 44: 156-163 (Pubitemid 30010687)
31. Frimodt-Moller N(2002) Correlation between pharmacokinetic/ pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 19: 546-553 (Pubitemid 34831659)
32. Bjerrum L, Gahrn-Hansen B, Grinsted P(2009) Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial. Scand J Prim Health Care 27: 6-11
33. Menday AP(2000) Comparison of pivmecillinam and cephalexin in acute uncomplicated urinary tract infection. Int J Antimicrob Agents 13: 183-187
34. Ferry SA, Holm SE, Stenlund H, Lundholm R, Monsen TJ(2007) Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. Scand J Prim Health Care 25: 49-57
35. Nicolle LE, Madsen KS, Debeeck GO, Blochlinger E, Borrild N et al.(2002) Three days of pivmecillinam or norfloxacin for treatment of acute uncomplicated urinary infection in women. Scand J Infect Dis 34: 487-492
36. Raz R, Gennesin Y, Wasser J, Stoler Z, Rosenfeld S et al.(2000) Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 30: 152-156 (Pubitemid 30067073)